REFERENCE
1. Kim MN, Kim BK, Han K-H. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region.Journal of gastroenterology 2013; 48 : 681-8.
2. Perumpail BJ, Khan MA, Yoo ER et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World journal of gastroenterology 2017; 23 : 8263.
3. McMillan HJ, Gregas M, Darras BT, Kang PB. Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy. Pediatrics2011; 127 : e132-e6.
4. Cicero AFG, Colletti A, Bellentani S. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients 2018; 10 .
5. Derosa G, Bonaventura A, Bianchi L et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 2013; 13 : 1495-506.
6. Derosa G, Romano D, D’Angelo A, Maffioli P. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis 2015;239 : 87-92.
7. Derosa G, Romano D, D’Angelo A, Maffioli P. Berberis aristata/Silybum marianum fixed combination (Berberol((R))) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine2015; 22 : 231-7.
8. Derosa G, D’Angelo A, Maffioli P. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. clnu 2016; 35 : 1091-5.
9. Guarino G, Della Corte T, Sofia M et al. Metabolic effects of the association Berberis aristata/Silybum marianum: a preliminary double-blind, placebo-controlled study in obese patients with type 2 diabetes. Nutrafoods 2015; 14 : 181-8.
10. Kathleen A. Berberine. Alternative Medicine Review 2000;5 : 175-7.
11. Kong W, Wei J, Abidi P et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature medicine 2004; 10 : 1344-51.
12. Lan J, Zhao Y, Dong F et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of ethnopharmacology 2015;161 : 69-81.
13. Lee S, Lim H-J, Park J-H et al. Berberine-induced LDLR up-regulation involves JNK pathway. Biochemical and biophysical research communications 2007; 362 : 853-7.
14. Lee YS, Kim WS, Kim KH et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55 : 2256-64.
15. Yao J, Kong W, Jiang J. Learning from berberine: Treating chronic diseases through multiple targets. Science china life sciences2015; 58 : 854-9.
16. Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert opinion on investigational drugs 2010; 19 : 1297-307.
17. Scott Luper N. A review of plants used in the treatment of liver disease: part 1. Alternative medicine review 1998; 3 : 410-21.
18. Zhou S, Lim LY, Chowbay B. Herbal modulation of P‐glycoprotein.Drug metabolism reviews 2004; 36 : 57-104.
19. Chang X, Yan H, Fei J et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 2010; 51 : 2504-15.
20. Zhao L, Cang Z, Sun H et al. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord 2017; 17 : 13.
21. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7 : 941-6.
22. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8 : 1288-95.
23. Li Y, Wang P, Zhuang Y et al. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. FEBS Lett 2011; 585 : 1735-40.
24. Kong W, Wei J, Abidi P et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10 : 1344-51.
25. Guo T, Woo SL, Guo X et al. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. Sci Rep 2016; 6 : 22612.
26. Saller R, Melzer J, Reichling J et al. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed 2007;14 : 70-80.
27. Morishima C, Shuhart MC, Wang CC et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology 2010; 138 : 671-81, 81.e1-2.
28. Tzeng JI, Chen MF, Chung HH, Cheng JT. Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride. Phytother Res 2013;27 : 1023-8.
29. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23 : 749-54.
30. Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res2019; 33 : 862-70.
31. Zhang BJ, Xu D, Guo Y et al. Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol 2008;35 : 303-9.
32. Yan H-M, Xia M-F, Wang Y et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PloS one 2015;10 : e0134172.
33. de Avelar CR, Pereira EM, de Farias Costa PR et al. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World J Gastroenterol 2017;23 : 5004-17.
34. Mirnezami M, Jafarimanesh H, Rezagholizamenjany M et al. The effect of silymarin on liver enzymes in patients taking isotretinoin: A randomized clinical trial. Dermatol Ther 2020: e13236.
35. Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study.Scand J Gastroenterol 1982; 17 : 517-21.
36. Feher J, Deak G, Muzes G et al. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. Orv Hetil 1989; 130 : 2723-7.
37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS medicine 2009; 6 : e1000097.
38. Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.Bmj 2011; 343 : d5928.
39. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5 : 13.
40. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22 : 719-48.
41. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007;28 : 105-14.
42. An Y, Sun Z, Zhang Y et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf) 2014; 80 : 425-31.
43. Liu Y-T, Hao H-P, Xie H-G et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug metabolism and disposition2010; 38 : 1779-84.
44. Liu Y, Hao H, Xie H et al. Oxidative demethylenation and subsequent glucuronidation are the major metabolic pathways of berberine in rats.J Pharm Sci 2009; 98 : 4391-401.
45. Di Pierro F, Villanova N, Agostini F et al. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes 2012; 5 : 213-7.
46. Derosa G, Bonaventura A, Bianchi L et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert opinion on biological therapy 2013;13 : 1495-506.
47. Derosa G, D’Angelo A, Maffioli P. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. Clinical nutrition 2016; 35 : 1091-5.
48. Di Pierro F, Bellone I, Rapacioli G, Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes 2015; 8 : 89-96.
49. Kong WJ, Wei J, Zuo ZY et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 2008;57 : 1029-37.
50. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.J Hepatol 1989; 9 : 105-13.
51. Federico A, Trappoliere M, Tuccillo C et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006; 55 : 901-2.
52. Aller R, Izaola O, Gómez S et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci 2015;19 : 3118-24.
53. Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D 2015; 15 : 21-5.